DiFabio Andrea 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 13, 2025
Insider Transaction Report
Form 4
DiFabio Andrea
Chief Legal Officer
Transactions
- Award
Share Option (Right to Buy)
2025-03-12+80,000→ 80,000 totalExercise: $35.48Exp: 2035-03-11→ Common Shares (80,000 underlying) - Award
Restricted Share Units
2025-03-12+15,000→ 15,000 totalExercise: $0.00→ Common Shares (15,000 underlying)
Footnotes (2)
- [F1]Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
- [F2]Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026.